Navigation Links
Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
Date:4/17/2008

ommercially-available gabapentin.

Absorption of commercially-available gabapentin is limited to a narrow region in the intestinal tract and can saturate at normal clinical doses. Once saturation occurs, additional gabapentin can not be absorbed. In addition, absorption rates can vary from patient to patient. In contrast, studies with both the immediate-release and the sustained-release formulations indicated that XP13512 was well-absorbed, converted rapidly to gabapentin and provided high bioavailability (>70 percent) and dose-proportional exposure.

"XP13512 is absorbed by high-capacity nutrient transporters located throughout the intestinal tract," said Ken Cundy, Ph.D., senior vice president, Preclinical Development for XenoPort. "The unique absorption mechanism of this compound overcomes the pharmacokinetic limitations of commercially-available gabapentin and allows for sustained, dose-proportional exposure to gabapentin."

About PIVOT RLS I (Study XP052)

PIVOT RLS I, a 12-week, multicenter, randomized, double-blind, placebo- controlled clinical trial of XP13512 was designed to assess efficacy and tolerability in adults with moderate-to-severe primary RLS. The study included 220 patients randomized to receive either XP13512 1200 mg (n=112) or placebo (n=108) once-daily at 5:00 p.m. with food. Co-primary endpoints in the study were mean change from baseline in the International Restless Legs Syndrome (IRLS) Scale total score and the proportion of responders (defined as ratings of 'very much improved' or 'much improved') on the investigator-rated Clinical Global Impression of Improvement (CGI-I) Scale at Week 12. Adverse events, vital signs and laboratory tests were used to assess tolerability.

Study results showed that the unadjusted mean change from baseline in IRLS Scale total score at Week 12 was significantly greater for XP13512 (-13.2) compared to placebo (-8.8) with an adjusted mean treatment difference of -4.0, 95% CI: (-6.
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid ... Network-Quality Improvement Organization (QIN-QIO) contract to a partnership led ... Effective August 1, WVMI will launch Quality Insights Quality ... Pennsylvania , Delaware ... The Network will engage providers and the community in ...
(Date:7/23/2014)... July 23, 2014 Research and ... "Global Electrophysiology Ablation Catheters Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation is ... destroy faulty electrical pathways from sections of the ... as cardiac arrhythmias). Cardiac arrhythmias can be of ...
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3Creekridge Capital Signs Several New Vendor Partners 2
... WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: ... a Phase I,trial of INNO-406, an orally ... or,treatment-intolerant chronic myelogenous leukemia, will be,presented at ... Annual,Meeting. The meeting takes place June 1- ...
... from various,clinical studies including a pivotal Phase III trial ... Nexavar (sorafenib) tablets will be presented at the Annual,Meeting ... USA from June 1 - 5, 2007. , On ... be held on June 4, 2007. Starting at around ...
Cached Medicine Technology:Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
(Date:7/23/2014)... have been focused on the regions of the coding ... form of amino acids thus proteins. But just before ... which controls the expression and activity of the adjacent ... role exerted such DNA fragment in tumor development. ... in collaboration with the group of Manel Esteller, Director ...
(Date:7/23/2014)... therapy combining salmon fibrin injections into the spinal cord ... restored voluntary motor function impaired by spinal cord injury, ... , In a study on rodents, Gail Lewandowski and ... developmental clock in a molecular pathway critical to the ... scaffold so that neuronal axons at the injury site ...
(Date:7/23/2014)... 23, 2014 This report defines and ... (Asia-Pacific, Europe, the Middle East & Africa, and Americas) ... and geography with analysis and forecasts of the global ... grow from over $10 billion in 2014 to nearly ... 5%. , browse 49 Market Tables and 10 ...
(Date:7/23/2014)... Battle Creek, MI (PRWEB) July 23, 2014 ... treatment program that gets clients off to a great ... they can believe in, has launched a new Internet ... , “Many people are surprised to learn that Internet ... sexual addiction or drug addiction, but that it’s trapping ...
(Date:7/23/2014)... (HealthDay News) -- Children and teens who lose a parent ... adulthood, a new study suggests. People who were children ... greater risk of death during the study period than those ... to the report. Although the study found an association ... premature death, it wasn,t designed to prove cause-and-effect. Also, ...
Breaking Medicine News(10 mins):Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2
... curb dementia, researchers say, , , TUESDAY, Nov. 18 (HealthDay ... new research suggests that the herb ginkgo biloba won,t ... found that giving a standardized dose of ginkgo biloba ... the incidence rate of dementia or Alzheimer,s disease," said ...
... of allergic reactions, other problems have surfaced with these ... - American women who turn to cosmetic treatments called ... as to the health risks these products pose, an ... recommended Tuesday. , The panel of independent experts urged ...
... , RESTON, Va., Nov. 18 ... D prescription drug benefit in 2008 are satisfied with their ... nationwide education and advocacy group for older Americans. , ... Similar surveys conducted over the last year found the same ...
... now the only over the counter treatment for chronic and acute ... prevents contamination of wounds and speeds up the healing process. ... ... the development of Wound-Be-Gone, all skin injuries, especially large, chronic wounds, ...
... 18 (Nasdaq: WHRTD ) World,Heart Corporation ... 2008, the Company received a letter from The NASDAQ ... with Marketplace,Rule 4310(c)(4) (the "Minimum Bid Price Rule") and ... at $1.00 per share or greater for at least ...
... WASHINGTON, Nov. 18 Over 2 million low-income Medicare,beneficiaries ... in,January. Changes to the 2009 Medicare Part D plans ... premiums they cannot afford or limit,access to their prescriptions, ... Law Center (NSCLC). Part D open enrollment runs from ...
Cached Medicine News:Health News:Ginkgo No Shield Against Alzheimer's 2Health News:Ginkgo No Shield Against Alzheimer's 3Health News:Wrinkle Fillers Need Better Label Warnings: FDA Panel 2Health News:Wrinkle Fillers Need Better Label Warnings: FDA Panel 3Health News:New Survey Shows Seniors Overwhelmingly Satisfied With Medicare Part D 2Health News:A Revolution in Wound Healing, Wound-Be-Gone Now the Only Over the Counter Treatment for Chronic and Acute Wounds 2Health News:A Revolution in Wound Healing, Wound-Be-Gone Now the Only Over the Counter Treatment for Chronic and Acute Wounds 3Health News:WorldHeart Regains Compliance With the Minimum Bid Price Rule 2Health News:2009 Medicare Part D Premiums to Rise Dramatically: Over 2 Million Low Income Beneficiaries At Risk 2
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... SL1 developed by STORZ MEDICAL is the ... in the field of kidney stone lithotripsy ... requirements to be met by orthopaedic apparatus ... been outlined above. The MINILITH SL1 is ...
... transportable, the Dornier Compact Delta lithotripsy system features ... patient. The systems shock source and C-arm are ... avoid the risk of misalignment. The therapy head ... its motorized lateral and horizontal movement and can ...
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
Medicine Products: